Michael L. Corman

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse et al. · Proceedings of the National Academy of Sciences · 1996 · 379 citations

Medicine, Neuroscience, Pharmacology +17

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 284 citations

Medicine, Neuroscience, Pharmacology +13

Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 <i>H</i> -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).

Patrick R. Verhoest, Douglas S. Chapin, Michael L. Corman et al. · Journal of Medicinal Chemistry · 2009 · 201 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives

Rodney C. Schnur, Michael L. Corman, Randall J. Gallaschun et al. · Journal of Medicinal Chemistry · 1995 · 199 citations

Medicine, Medicinal Chemistry, Pharmacology +7

erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships

Rodney C. Schnur, Michael L. Corman, Randall J. Gallaschun et al. · Journal of Medicinal Chemistry · 1995 · 139 citations

Medicine, Medicinal Chemistry, Pharmacology +11